Pediatric Babesiosis Workup
- Author: Vinod K Dhawan, MD, FACP, FRCP(C); Chief Editor: Russell W Steele, MD more...
Laboratory Studies
The following may be observed in patients with babesiosis:
- Hemolytic anemia, decreased serum haptoglobin levels, and elevated reticulocyte counts are noted, and the anemia may occasionally be severe.
- The percentage of erythrocytes parasitized in clinical cases is usually 1-10% but has ranged from less than 1% to 85%.
- The total leukocyte count may be within the reference range or mildly decreased.
- Thrombocytopenia is common.
- The erythrocyte sedimentation rate may be elevated.
- Coombs test may react positively.
- Urinalysis reveals proteinuria and hemoglobinuria.
- BUN and serum creatinine levels may be elevated.
- The following usually have mildly elevated levels:
- Serum bilirubin
- Alkaline phosphatase
- Serum aspartate aminotransferase (AST)
- Serum glutamic-oxaloacetic transaminase (SGOT)
- Serum alanine aminotransferase (ALT)
- Serum glutamic-pyruvic transaminase (SGPT)
- Lactic dehydrogenase (LDH)
Other Tests
Babesiosis is usually diagnosed by microscopic examination of Giemsa-stained or Wright-stained thin or thick blood smears (see the image below).
Blood smear showing Babesia species in erythrocytes. Courtesy of the Centers for Disease Control and Prevention. Babesia may be mistaken for malarial parasite, particularly the ring forms of P falciparum. Helpful features that distinguish Babesia from Plasmodium include the absence of brownish pigment deposits (hemozoin), the lack of synchronous stages (schizonts and gametocytes observed with Plasmodium species), and the occasional presence of tetrads (as seen in the image below) of merozoites or Maltese-cross forms.
Babesia species, tetrad formation. Courtesy of the Centers for Disease Control and Prevention. Babesia varies more in shape and in size and may be observed outside erythrocytes with heavier infestation.
An indirect immunofluorescent antibody (IFA) assay can be used to make a serologic diagnosis of babesiosis.
A titer of 1:256 or greater is considered diagnostic for recent Babesia microti infection. Most patients with an active infection develop serum titers 1:024 or greater within a few weeks. Antibody titers decline slowly over months to 1:256 or less. Titers of 1:32 or less indicate prior infection. Cross-reactions may occur in serum specimens from patients with malaria infections.
Because of the antigenic differences, infections with WA-1 species and MO-1 strain Babesia are not detected by IFA for B microti. Test individuals whose exposure could have occurred on the West Coast of the United States for antibodies to the WA-1 species Babesia.
A polymerase chain reaction (PCR)–based diagnostic assay has been reported and holds great promise for increasing the detection rate of very low-level parasitemia. Persistence of antibody titers for B microti has been shown to correlate with the detection of babesial DNA by PCR.[5] In 1998, Krause and colleagues reported the detection of babesial DNA by PCR for as long as 27 months after untreated infection.[6]
Currently, the suspected B microti infection can be confirmed through intraperitoneal inoculation of 1 mL of ethylenediaminetetraacetic acid (EDTA) whole blood into the peritoneum of golden hamsters. B divergens replicates readily in gerbils. Within 2-4 weeks, smears are positive in the infected animals.
Consider the possibility of co-infection with Lyme disease because the 2 organisms share the same tick vector. Co-infection often results in increased duration and severity of illness.
Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am. Sep 2008;22(3):469-88. [Medline].
Vannier E, Krause PJ. Update on babesiosis. Interdiscip Perspect Infect Dis. 2009;2009:984568. [Medline].
Ngo V, Civen R. Babesiosis acquired through blood transfusion, California, USA. Emerg Infect Dis. May 2009;15(5):785-7. [Medline].
White DJ, Talarico J, Chang HG, et al. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med. Oct 26 1998;158(19):2149-54. [Medline].
Persing DH, Mathiesen D, Marshall WF, Telford SR, Spielman A, Thomford JW, et al. Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol. Aug 1992;30(8):2097-103. [Medline]. [Full Text].
Krause PJ, Spielman A, Telford SR 3rd, et al. Persistent parasitemia after acute babesiosis. N Engl J Med. Jul 16 1998;339(3):160-5. [Medline]. [Full Text].
Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. Feb 1 2008;46(3):370-6. [Medline].
Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. Nov 16 2000;343(20):1454-8. [Medline]. [Full Text].
Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. Clin Infect Dis. Dec 15 2007;45(12):1588-90. [Medline].
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis. Feb 1 2010;50(3):381-6. [Medline].
Kuwayama DP, Briones RJ. Spontaneous splenic rupture caused by Babesia microti infection. Clin Infect Dis. May 1 2008;46(9):e92-5. [Medline].
Benezra D, Brown AE, Polsky B, et al. Babesiosis and infection with human immunodeficiency virus (HIV). Ann Intern Med. Dec 1987;107(6):944. [Medline].
Buckingham SC. Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies. Paediatr Drugs. 2005;7(3):163-76. [Medline].
Cunha BA, Nausheen S, Szalda D. Pulmonary complications of babesiosis: case report and literature review. Eur J Clin Microbiol Infect Dis. Jul 2007;26(7):505-8. [Medline].
Dobroszycki J, Herwaldt BL, Boctor F, et al. A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor. JAMA. Mar 10 1999;281(10):927-30. [Medline].
Dorman SE, Cannon ME, Telford SR 3rd, et al. Fulminant babesiosis treated with clindamycin, quinine, and whole-blood exchange transfusion. Transfusion. Mar 2000;40(3):375-80. [Medline].
Falagas ME, Klempner MS. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Clin Infect Dis. May 1996;22(5):809-12. [Medline].
Florescu D, Sordillo PP, Glyptis A, et al. Splenic infarction in human babesiosis: two cases and discussion. Clin Infect Dis. Jan 1 2008;46(1):e8-11. [Medline].
Fox LM, Wingerter S, Ahmed A, et al. Neonatal babesiosis: case report and review of the literature. Pediatr Infect Dis J. Feb 2006;25(2):169-73. [Medline].
Gelfand JA, Callahan MV. Babesiosis. Curr Clin Top Infect Dis. 1998;18:201-16. [Medline].
Genchi C. Human babesiosis, an emerging zoonosis. Parassitologia. May 2007;49 Suppl 1:29-31. [Medline].
Gorenflot A, Moubri K, Precigout E, et al. Human babesiosis. Ann Trop Med Parasitol. Jun 1998;92(4):489-501. [Medline].
Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis. May 1997;175(5):1259-62. [Medline].
Homer MJ, Aguilar-Delfin I, Telford SR 3rd, Krause PJ, Persing DH. Babesiosis. Clin Microbiol Rev. Jul 2000;13(3):451-69. [Medline]. [Full Text].
Hunfeld KP, Hildebrandt A, Gray JS. Babesiosis: recent insights into an ancient disease. Int J Parasitol. Sep 2008;38(11):1219-37. [Medline].
Jacoby GA, Hunt JV, Kosinski KS, et al. Treatment of transfusion-transmitted babesiosis by exchange transfusion. N Engl J Med. Nov 6 1980;303(19):1098-100. [Medline].
Kjemtrup AM, Conrad PA. Human babesiosis: an emerging tick-borne disease. Int J Parasitol. Nov 1 2000;30(12-13):1323-1337. [Medline].
Krause PJ, Telford SR, Spielman A, et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA. Jun 5 1996;275(21):1657-60. [Medline].
Linden JV, Wong SJ, Chu FK, et al. Transfusion-associated transmission of babesiosis in New York State. Transfusion. Mar 2000;40(3):285-9. [Medline].
Persing DH, Herwaldt BL, Glaser C, Lane RS, Thomford JW, Mathiesen D, et al. Infection with a babesia-like organism in northern California. N Engl J Med. Feb 2 1995;332(5):298-303. [Medline]. [Full Text].
Pfeiffer CD, Kazmierczak JJ, Davis JP. Epidemiologic features of human babesiosis in Wisconsin, 1996-2005. WMJ. Jul 2007;106(4):191-5. [Medline].
Quick RE, Herwaldt BL, Thomford JW, et al. Babesiosis in Washington State: a new species of Babesia?. Ann Intern Med. Aug 15 1993;119(4):284-90. [Medline]. [Full Text].
Raju M, Salazar JC, Leopold H, Krause PJ. Atovaquone and azithromycin treatment for babesiosis in an infant. Pediatr Infect Dis J. Feb 2007;26(2):181-3. [Medline].
Rios L, Alvarez G, Blair S. Serological and parasitological study and report of the first case of human babesiosis in Columbia. Rev Soc Bras Med Trop. 2003;36:493-8. [Medline].
Rodgers SE, Mather TN. Human Babesia microti incidence and Ixodes scapularis distribution, Rhode Island, 1998-2004. Emerg Infect Dis. Apr 2007;13(4):633-5. [Medline].
Saito-Ito A, Tsuji M, Wei Q, et al. Transfusion-acquired, autochthonous human babesiosis in Japan: isolation of Babesia microti-like parasites with hu-RBC-SCID mice. J Clin Microbiol. Dec 2000;38(12):4511-6. [Medline]. [Full Text].
Vannier E, Borggraefe I, Telford SR, et al. Age-associated decline in resistance to Babesia microti is genetically determined. J Infect Dis. May 1 2004;189(9):1721-8. [Medline].
Wittner M, Lederman J, Tanowitz HB, et al. Atovaquone in the treatment of Babesia microti infections in hamsters. Am J Trop Med Hyg. Aug 1996;55(2):219-22. [Medline].
Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. Nov 1 2006;43(9):1089-134. [Medline].

